Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00137969 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus
A Phase 2 study of Lupus Erythematosus, Systemic, sponsored by Genentech.
- Completed
- Registry status
- Phase 2
- Development phase
- 262
- Enrollment target
- 20
- Study locations
NCT00137969 is a Phase 2 study of Lupus Erythematosus, Systemic that has completed, run by Genentech. The registered enrollment target is 262 participants, above the 194-participant average among 29 other Lupus Erythematosus, Systemic trials with a reported enrollment target (35% higher). The trial reports 20 study locations across 10 states.
The verdict
NCT00137969, a Phase 2 study of Lupus Erythematosus, Systemic, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 262 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase II/III, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of rituximab compared with placebo when combined with a single stable background immunosuppressive medication in subjects with moderate to severe systemic lupus erythematosus (SLE). The primary efficacy endpoint of the trial will be evaluated at 52 weeks.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Acetaminophen
- DRUG Rituximab
- DRUG Prednisone
- DRUG Diphenhydramine
Study Locations (20)
California
- Univ of California, San Diego - La Jolla
- Univ of Calif., Los Angeles; Rheumatology - Los Angeles
- Cedars-Sinai Medical Center - Los Angeles
- Stanford University Med Ctr;Div of Immunology/Rheumatology - Palo Alto
- Univ of Calif, San Francisco; Rheumatology - San Francisco
- Eden Medical Center San Leandro Hospital - San Leandro
Illinois
- Northwestern University - Chicago
- Rheumatology Associates - Chicago
- University of Chicago - Chicago
Alabama
- Univ of Alabama School of Med; Clinical Immun Rheumatology - Birmingham
- Rheumatology Assoc of North AL - Huntsville
Florida
- Arthritis & Rheumatism; Disease Specialities - Aventura
- Family Arthritis Center - Jupiter
Idaho
- Intermountain Research Center - Boise
- Coeur D'Alene Arthritis Clinic - Coeur d'Alene
Arizona
- Arizona Arthritis & Rheumatology Research, Pllc - Paradise Valley
Colorado
- University of Colorado Denver - Aurora
Georgia
- Emory Uni ; Division of Rheumatology - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 262 participants |
| Start Date | 2005-05-10 |
| Est. Completion | 2008-08-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00137969
The ClinicalTrials.gov registry entry for NCT00137969 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 262 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 194-participant average among 29 other Lupus Erythematosus, Systemic trials with a reported enrollment target (35% higher). The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lupus Erythematosus, Systemic appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.
NCT00137969 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Illinois, Alabama.
Frequently Asked Questions
What is clinical trial NCT00137969 about?
NCT00137969 is a clinical study titled "A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus". This is a Phase II/III, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of rituximab compared with placebo when combined with a single stable background immunosuppressive medication in subjects with moderate to severe systemic lupus erythematosus (...
What is the current status of trial NCT00137969?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 262 participants. The study started on 2005-05-10. Estimated completion is 2008-08-25.
What conditions does trial NCT00137969 study?
This clinical trial studies the following conditions: Lupus Erythematosus, Systemic.
What interventions are being tested in trial NCT00137969?
The interventions under investigation include: Placebo (DRUG), Acetaminophen (DRUG), Rituximab (DRUG), Prednisone (DRUG), Diphenhydramine (DRUG).
Who is sponsoring clinical trial NCT00137969?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00137969 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lupus Erythematosus, Systemic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)
RECRUITING · Phase 2
-
A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)
RECRUITING · Phase 2
-
Memantine for the Treatment of Cognitive Impairment in Systemic Lupus Erythematosus
ACTIVE NOT RECRUITING · Phase 2
-
Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Lesions
COMPLETED · Phase 2
-
Study of VIB7734 for the Treatment of Moderate to Severely Active SLE
COMPLETED · Phase 2
-
An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in Adults
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.